Assistant Professor, Radiation Oncology, Tufts Medical Center
Radiation Oncology
Dr. Thomas A. Dipetrillo, MD
|
|
Give Review
Thomas A. Dipetrillo is an expert in the field of Radiation Oncology. He studied medicine at University of Vermont College of Medicine. He received awards:"Regional Top Doctor". Thomas A. Dipetrillo, MD is a published doctor. He published 75 publications, including: 'Dosimetric verification of the dynamic intensity-modulated radiation therapy of 92 patients.' He accepts Medicare payments and is listed with Medicare.gov.
Publications
- Glycogen Synthase Kinase 3β predicts survival in adenocarcinoma of the pancreas.
- Local recurrence and survival following stereotactic radiosurgery for brain metastases from small cell lung Cancer.
- Breast Boost Using Noninvasive Image-Guided Breast Brachytherapy vs. External Beam: A 2:1 Matched-Pair Analysis.
- Patterns of care of radiation therapy in patients with stage IV rectal Cancer: A Surveillance, Epidemiology, and End Results analysis of patients from 2004 to 2009.
- 37. ADXS11-001, mitomycin, 5-FU and radiation for anal Cancera A phase I/II study.
- Cost and effectiveness of radiofrequency ablation versus limited surgical resection for stage I non-small-cell lung Cancer in elderly patients: is less more?
- The Effect of Dose-Volume Parameters and Interfraction Interval on Cosmetic Outcome and Toxicity After 3-Dimensional Conformal Accelerated Partial Breast Irradiation.
- Paclitaxel Poliglumex, Temozolomide, and Radiation for Newly Diagnosed High-grade Glioma: A Brown University Oncology Group Study.
- Dosimetric Feasibility of Dose Escalation Using SBRT Boost for Stage III Non-Small Cell Lung Cancer.
- Charlson Comorbidity Index predicts patient outcome, in cases of inoperable non-small cell lung Cancer treated with radiofrequency ablation.
- Thirty- and ninety-day outcomes after sublobar resection with and without brachytherapy for non-small cell lung Cancer: Results from a multicenter phase III study.
- Pathologic response after neoadjuvant carboplatin and weekly paclitaxel for early-stage lung Cancer: a Brown University oncology group phase II study.
- The impact of adjuvant brachytherapy with sublobar resection on pulmonary function and dyspnea in high-risk patients with operable disease: Preliminary results from th...
- Combined radiofrequency ablation and high-dose rate brachytherapy for early-stage non-small-cell lung Cancer.
- A novel ytterbium-169 brachytherapy source and delivery system for use in conjunction with minimally invasive wedge resection of early-stage lung Cancer.
- Image-guided tumor ablation for the treatment of recurrent non-small cell lung Cancer within the radiation field.
- Pneumonectomy after neoadjuvant chemotherapy and radiation for advanced-stage lung Cancer.
- Microwave ablation of lung malignancies: effectiveness, CT findings, and safety in 50 patients.
- Long-term outcome and toxicity in a Phase I/II trial using high-dose-rate multicatheter interstitial brachytherapy for T1/T2 breast Cancer.
- Image-guided percutaneous thermal ablation for the palliative treatment of chest wall masses.
- Role of adjuvant radiation (external beam/brachytherapy) for stage I NSCLC.
- Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients.
- Dose-modeling study to compare external beam techniques from protocol NSABP B-39/RTOG 0413 for patients with highly unfavorable cardiac anatomy.
- Percutaneous image-guided thermal ablation and radiation therapy: outcomes of combined treatment for 41 patients with inoperable stage I/II non-small-cell lung Cancer.
- Persistent seroma after intraoperative placement of MammoSite for accelerated partial breast irradiation: incidence, pathologic anatomy, and contributing factors.
- Accelerated partial breast irradiation: current modalities and investigations.
- MammoSite excision volume as a predictor for residual disease.
- Percutaneous radiofrequency ablation of pulmonary malignancies: combined treatment with brachytherapy.
- ErbB2 degradation mediated by the co-chaperone protein CHIP.
- Limited resection for non-small cell lung Cancer: observed local control with implantation of I-125 brachytherapy seeds.
- Preliminary results of a phase I/II study of HDR brachytherapy alone for T1/T2 breast Cancer.
- Accelerated partial breast irradiation: an analysis of variables associated with late toxicity and long-term cosmetic outcome after high-dose-rate interstitial brachyt...
- Radiofrequency ablation followed by conventional radiotherapy for medically inoperable stage I non-small cell lung Cancer.
- Neoadjuvant Paclitaxel poliglumex, Cisplatin, and radiation for esophageal Cancer: a phase 2 trial.
- Percutaneous radiofrequency ablation of painful osseous metastases: a multicenter American College of Radiology Imaging Network trial.
- Carboplatin with weekly docetaxel and ifosfamide in advanced head and neck Cancers: a phase I Brown University Oncology Group dose escalation study (HN-93).
- Chemoradiotherapy and gefitinib in stage III non-small cell lung Cancer with epidermal growth factor receptor and KRAS mutation analysis: Cancer and leukemia group B (...
- Lapatinib/gemcitabine and lapatinib/gemcitabine/oxaliplatin: a phase I study for advanced pancreaticobiliary Cancer.
- Intensity-modulated radiotherapy of the prostate after cryotherapy: initial experience.
- Planning the breast boost: comparison of three techniques and evolution of tumor bed during treatment.
- Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation.
- Cetuximab, paclitaxel, carboplatin, and radiation for head and neck Cancer: a toxicity analysis.
- Cetuximab with concurrent chemoradiation for esophagogastric Cancer: assessment of toxicity.
- Preliminary results and evaluation of MammoSite balloon brachytherapy for partial breast irradiation for pure ductal carcinoma in situ: a phase II clinical study.
- Phase I/II study of trastuzumab, paclitaxel, cisplatin and radiation for locally advanced, HER2 overexpressing, esophageal adenocarcinoma.
- Multimodality treatment of esophageal Cancer: a review of the current status and future directions.
- MammoSite and interstitial brachytherapy for accelerated partial breast irradiation: factors that affect toxicity and cosmesis.
- Trastuzumab, paclitaxel, cisplatin, and radiation for adenocarcinoma of the esophagus: a phase I study.
- Implementation and utility of a daily ultrasound-based localization system with intensity-modulated radiotherapy for prostate Cancer.
- Gemcitabine, paclitaxel, and radiation for locally advanced pancreatic Cancer: a Phase I trial.
- Clinical applications of radio-frequency tumor ablation in the thorax.
- Treatment of the axilla by tangential breast radiotherapy in women with invasive breast Cancer.
- Long-term follow-up of a prospective policy of margin-directed radiation dose escalation in breast-conserving therapy.
- The value of breast lumpectomy margin assessment as a predictor of residual tumor burden in ductal carcinoma in situ of the breast.
- Pneumonectomy after high-dose radiation and concurrent chemotherapy for nonsmall cell lung Cancer.
- Margin width as a determinant of local control with and without radiation therapy for ductal carcinoma in situ (DCIS) of the breast.
- Paclitaxel and concurrent radiation for locally advanced pancreatic Cancer.
- Anti-inflammatory adrenal steroids that neither inhibit skin collagen synthesis nor cause dermal atrophy.
- Paclitaxel and concurrent radiation for gastric Cancer.
- Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma.
- Inhibition of collagen accumulation by glucocorticoids in rat lung after intratracheal bleomycin instillation.
- Breast conservation in elderly women for clinically negative axillary lymph nodes without axillary dissection.
- Breast conservation therapy for early stage breast carcinoma with outstanding 10-year locoregional control rates: a case for aggressive therapy to the tumor bearing qu...
- Dosimetric verification of the dynamic intensity-modulated radiation therapy of 92 patients.
- A non-invasive immobilization system and related quality assurance for dynamic intensity modulated radiation therapy of intracranial and head and neck disease.
- The influence of age and extensive intraductal component histology upon breast lumpectomy margin assessment as a predictor of residual tumor.
- Emergence of increased cerebral metastasis after high-dose preoperative radiotherapy with chemotherapy in patients with locally advanced nonsmall cell lung carcinoma.
- Optimal radiotherapy for prostate Cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models.
- Bleomycin-induced increase of collagen turnover in IMR-90 fibroblasts: an in vitro model of connective tissue restructuring during lung fibrosis.
- Variation of corticosteroid-induced inhibition of collagen synthesis at equivalent anti-inflammatory doses.
- Three-dimensional conformal radiotherapy for early stage prostatic Cancer: techniques, outcomes, and possible pitfalls.
- High dose radiation therapy and chemotherapy as induction treatment for stage III nonsmall cell lung carcinoma.
- Dexamethasone decreases the amounts of type I procollagen mRNAs in vivo and in fibroblast cell cultures.
- Clinically evident fat necrosis in women treated with high-dose-rate brachytherapy alone for early-stage breast Cancer.
Schools
University Of Vermont College Of Medicine
New England Med Center Hosps
Newton Wellesley Hospital
Conditions Treated
- Vulvar Cancer
Doctors Specialties
- Internal Medicine
- Radiation Oncology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
Tufts Medical Center -
University of Vermont College of Medicine
Hospital
-
Rhode Island Hospital -
Tufts Medical Center
Drug Facts
| NPI NUMBER | 1881651941 | |
| NPPES Provider LastName | DIPETRILLO | |
| NPPES Provider FirstName | THOMAS | |
| NPPES Provider ZIPCode | 029034923 | |
| NPPES Provider State | RI | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 85.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1881651941 |
| Last Name Of The Provider | DIPETRILLO |
| First Name Of The Provider | THOMAS |
| View All |
Similar Doctors
|
|
Dr. Kathy A. Radie-Keane, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Darlene Gabeau, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Mohamedyakub A. Puthawala, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joanne Zhung, MD |
|
|
Dr. Alexandra Sherman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Casey J. Maks, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kara L. Leonard, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew J. Abrams, MD |
|
Dr. Nicklas B. Oldenburg, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Roger Brotman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David E. Wazer, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Gabriela B. Masko, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Kathy A. Radie-Keane, MD |
|
|
Dr. Allison Crawford, MD |
|
|
Dr. Elizabeth Horn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kate E. Mavrich, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christine M. Ho, MD |
|
|
Dr. Visalakshi Kunapuli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jaroslaw Hepel, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amy Goldfarb, MD
This Doctor is OpenDoctor Recommended.
|